GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Interest Paid

Tvardi Therapeutics (LTS:0HTC) Interest Paid


View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Interest Paid?

Interest Paid only applicable to companies reporting Cash Flow from Operations in direct method.


Tvardi Therapeutics Business Description

Traded in Other Exchanges
Address
3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Website
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.